loading
Neurocrine Biosciences Inc stock is traded at $122.25, with a volume of 915.59K. It is up +0.80% in the last 24 hours and down -18.88% over the past month. Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.
See More
Previous Close:
$121.28
Open:
$120.19
24h Volume:
915.59K
Relative Volume:
1.03
Market Cap:
$12.34B
Revenue:
$2.12B
Net Income/Loss:
$339.20M
P/E Ratio:
65.73
EPS:
1.86
Net Cash Flow:
$494.60M
1W Performance:
+1.73%
1M Performance:
-18.88%
6M Performance:
-13.79%
1Y Performance:
+6.96%
1-Day Range:
Value
$119.82
$123.39
1-Week Range:
Value
$118.04
$123.39
52-Week Range:
Value
$103.63
$157.98

Neurocrine Biosciences Inc Stock (NBIX) Company Profile

Name
Name
Neurocrine Biosciences Inc
Name
Phone
(858) 617-7600
Name
Address
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Name
Employee
1,500
Name
Twitter
Name
Next Earnings Date
2024-08-01
Name
Latest SEC Filings
Name
NBIX's Discussions on Twitter

Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-13-23 Resumed Citigroup Neutral
Dec-12-23 Initiated Deutsche Bank Buy
Oct-24-23 Resumed Cantor Fitzgerald Overweight
Aug-21-23 Reiterated Mizuho Neutral
Jul-24-23 Upgrade SVB Securities Market Perform → Outperform
Jul-06-23 Upgrade BMO Capital Markets Underperform → Market Perform
May-04-23 Upgrade Guggenheim Neutral → Buy
Mar-30-23 Upgrade Canaccord Genuity Hold → Buy
Mar-03-23 Upgrade Evercore ISI In-line → Outperform
Feb-03-23 Upgrade Morgan Stanley Equal-Weight → Overweight
Nov-14-22 Downgrade Evercore ISI Outperform → In-line
Oct-11-22 Initiated UBS Buy
Sep-26-22 Initiated Wells Fargo Equal Weight
Jun-06-22 Resumed Jefferies Buy
Mar-03-22 Downgrade Piper Sandler Overweight → Neutral
Feb-25-22 Upgrade Goldman Neutral → Buy
Jan-18-22 Downgrade RBC Capital Mkts Outperform → Sector Perform
Nov-19-21 Initiated BMO Capital Markets Underperform
Nov-17-21 Upgrade JP Morgan Neutral → Overweight
Oct-14-21 Downgrade Morgan Stanley Overweight → Equal-Weight
Sep-23-21 Resumed Needham Hold
Aug-06-21 Downgrade Canaccord Genuity Buy → Hold
May-18-21 Resumed Goldman Neutral
May-06-21 Upgrade Barclays Equal Weight → Overweight
Feb-02-21 Initiated Raymond James Outperform
Sep-30-20 Initiated The Benchmark Company Hold
Aug-04-20 Downgrade JP Morgan Overweight → Neutral
Jun-29-20 Downgrade Goldman Buy → Neutral
Jun-09-20 Initiated Wedbush Outperform
Mar-06-20 Initiated Citigroup Buy
Feb-27-20 Initiated Barclays Equal Weight
Feb-24-20 Initiated William Blair Outperform
Feb-06-20 Initiated Mizuho Neutral
Feb-05-20 Reiterated H.C. Wainwright Buy
Dec-13-19 Downgrade Credit Suisse Outperform → Neutral
Aug-07-19 Initiated RBC Capital Mkts Outperform
Jul-16-19 Initiated Oppenheimer Outperform
Jun-05-19 Initiated Guggenheim Neutral
May-21-19 Initiated Credit Suisse Outperform
Apr-22-19 Upgrade JP Morgan Neutral → Overweight
Apr-12-19 Initiated Evercore ISI Outperform
Feb-06-19 Reiterated BofA/Merrill Buy
Jan-23-19 Downgrade JP Morgan Overweight → Neutral
Dec-13-18 Initiated Goldman Buy
Nov-21-18 Initiated Canaccord Genuity Buy
View All

Neurocrine Biosciences Inc Stock (NBIX) Latest News

pulisher
05:35 AM

Dai ichi Life Insurance Company Ltd Has $6.67 Million Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat

05:35 AM
pulisher
Sep 14, 2024

Neurocrine Biosciences, Inc. (NBIX): Hedge Funds Are Bullish on This Aggressive Growth Stock - Yahoo Finance

Sep 14, 2024
pulisher
Sep 13, 2024

Cornercap Investment Counsel Inc. Invests $1.22 Million in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat

Sep 13, 2024
pulisher
Sep 13, 2024

Neurocrine Shifts Focus To New Schizophrenia Treatment After Luvadaxistat Trial Misses Endpoint - Benzinga

Sep 13, 2024
pulisher
Sep 13, 2024

Neurocrine’s Phase II schizophrenia trial fails to meet primary endpoint - Clinical Trials Arena

Sep 13, 2024
pulisher
Sep 12, 2024

Neurocrine halts luvadaxistat development after trial miss - Investing.com

Sep 12, 2024
pulisher
Sep 12, 2024

Neurocrine halts development of schizophrenia drug as trial fails - AOL

Sep 12, 2024
pulisher
Sep 12, 2024

Neurocrine ending development of luvadaxistat amid failed study (NASDAQ:NBIX) - Seeking Alpha

Sep 12, 2024
pulisher
Sep 12, 2024

Neurocrine Biosciences's Schizophrenia Treatment Misses Endpoint - MarketWatch

Sep 12, 2024
pulisher
Sep 12, 2024

Neurocrine Biosciences (NBIX) Provides Update on ERUDITE Phase 2 Data for Luvadaxistat - StreetInsider.com

Sep 12, 2024
pulisher
Sep 12, 2024

Neurocrine Biosciences Provides Update on ERUDITE™ Phase 2 Data for Luvadaxistat in Adults with Cognitive Impairment Associated with Schizophrenia - StockTitan

Sep 12, 2024
pulisher
Sep 12, 2024

Levodopa-induced Dyskinesia Market Growth Anticipated by 2032 - openPR

Sep 12, 2024
pulisher
Sep 12, 2024

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Savant Capital LLC - MarketBeat

Sep 12, 2024
pulisher
Sep 12, 2024

Analysts Set Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Price Target at $162.20 - MarketBeat

Sep 12, 2024
pulisher
Sep 12, 2024

Neurocrine Biosciences Provides Update on ERUDITE™ Phase 2 Data for Luvadaxistat in Adults with Cognitive Impairment Associated with Schizophrenia - MSN

Sep 12, 2024
pulisher
Sep 11, 2024

Rice Hall James & Associates LLC Reduces Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat

Sep 11, 2024
pulisher
Sep 10, 2024

Huntington's Disease Market Forecasted to Surge in Coming - openPR

Sep 10, 2024
pulisher
Sep 10, 2024

Neurocrine Biosciences to Participate at the 2024 Cantor Global Healthcare Conference - StockTitan

Sep 10, 2024
pulisher
Sep 10, 2024

Andra AP fonden Buys 86,900 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat

Sep 10, 2024
pulisher
Sep 09, 2024

Neurocrine Biosciences (NASDAQ:NBIX) PT Lowered to $160.00 at Barclays - MarketBeat

Sep 09, 2024
pulisher
Sep 09, 2024

Decoding 19 Analyst Evaluations For Neurocrine Biosciences - Benzinga

Sep 09, 2024
pulisher
Sep 09, 2024

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock Holdings Reduced by Los Angeles Capital Management LLC - MarketBeat

Sep 09, 2024
pulisher
Sep 08, 2024

Great Lakes Advisors LLC Has $15.32 Million Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat

Sep 08, 2024
pulisher
Sep 07, 2024

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock Position Raised by Candriam S.C.A. - MarketBeat

Sep 07, 2024
pulisher
Sep 05, 2024

When (NBIX) Moves Investors should Listen - Stock Traders Daily

Sep 05, 2024
pulisher
Sep 03, 2024

Fiera Capital Corp Raises Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat

Sep 03, 2024
pulisher
Sep 03, 2024

Tardive Dyskinesia (TD) Market Research 2024: Epidemiology, Treatment Landscape, Unmet Needs, Emerging Therapies, and Value & Access - GlobeNewswire Inc.

Sep 03, 2024
pulisher
Sep 02, 2024

Nxera wins $35m after Phase II schizophrenia trial success - Clinical Trials Arena

Sep 02, 2024
pulisher
Sep 02, 2024

Nxera wins $35m after Phase II schizophrenia trial success - Pharmaceutical Technology

Sep 02, 2024
pulisher
Sep 02, 2024

Dollar General, Temu Parent PDD And Super Micro Computer Are Among Top 10 Large Cap Losers Last Week (Aug 25-Aug 31): Are The Others In Your Portfolio? - Benzinga

Sep 02, 2024
pulisher
Sep 02, 2024

Nxera Pharma to receive $35 million from Neurocrine | Biotechnology | The Pharmaletter - The Pharma Letter

Sep 02, 2024
pulisher
Sep 02, 2024

Nxera Pharma Ltd collects clinical US$35m milestone - European Biotechnology News

Sep 02, 2024
pulisher
Sep 02, 2024

Van ECK Associates Corp Purchases 3,976 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat

Sep 02, 2024
pulisher
Sep 01, 2024

Nxera Pharma to Receive US$35 Million from Neurocrine Biosciences upon Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568 - Yahoo Finance

Sep 01, 2024
pulisher
Sep 01, 2024

GraniteShares Advisors LLC Makes New $543,000 Investment in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat

Sep 01, 2024
pulisher
Aug 31, 2024

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Holdings Trimmed by Principal Financial Group Inc. - MarketBeat

Aug 31, 2024
pulisher
Aug 30, 2024

Neurocrine Stock Down 19% on Mixed Schizophrenia Study Results - MSN

Aug 30, 2024
pulisher
Aug 30, 2024

BNP PARIBAS ASSET MANAGEMENT Holding S.A. Sells 1,607,323 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat

Aug 30, 2024
pulisher
Aug 30, 2024

Why Neurocrine Biosciences Stock Was Tumbling This Week - Yahoo Finance

Aug 30, 2024
pulisher
Aug 30, 2024

Neurocrine Biosciences (NASDAQ:NBIX) Given New $155.00 Price Target at Cantor Fitzgerald - Defense World

Aug 30, 2024
pulisher
Aug 29, 2024

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Acquired by Zurcher Kantonalbank Zurich Cantonalbank - MarketBeat

Aug 29, 2024
pulisher
Aug 29, 2024

Neurocrine Biosciences' Lower Dose Data Puts Its Schizophrenia Candidate In The Game, Analyst Upgrades Stock - AOL

Aug 29, 2024
pulisher
Aug 29, 2024

Neurocrine Biosciences’ (NBIX) Buy Rating Reiterated at HC Wainwright - Defense World

Aug 29, 2024
pulisher
Aug 29, 2024

Neurocrine Biosciences' Lower Dose Data Puts Its Schizophrenia Candidate In The Game, Analyst Upgrades Stock - Yahoo Finance

Aug 29, 2024
pulisher
Aug 29, 2024

Cantor Fitzgerald Cuts Neurocrine Biosciences (NASDAQ:NBIX) Price Target to $155.00 - MarketBeat

Aug 29, 2024
pulisher
Aug 29, 2024

StockWatch: Neurocrine Tumbles as Schizophrenia Data Disappoints - Genetic Engineering & Biotechnology News

Aug 29, 2024
pulisher
Aug 29, 2024

Neurocrine Stock Down 19% on Mixed Schizophrenia Study Results - Yahoo Finance

Aug 29, 2024
pulisher
Aug 29, 2024

Neurocrine upped to overweight by Piper, sees '568 as still viable (NASDAQ:NBIX) - Seeking Alpha

Aug 29, 2024
pulisher
Aug 29, 2024

Neurocrine Biosciences (NASDAQ:NBIX) Earns Buy Rating from HC Wainwright - MarketBeat

Aug 29, 2024
pulisher
Aug 29, 2024

Neurocrine’s schizophrenia drug succeeds at phase 2, but dosing questions remain - BioPharma-Reporter.com

Aug 29, 2024
pulisher
Aug 29, 2024

Neurocrine Biosciences (NASDAQ:NBIX) Stock Rating Reaffirmed by Needham & Company LLC - Defense World

Aug 29, 2024

Neurocrine Biosciences Inc Stock (NBIX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
drug_manufacturers_specialty_generic RDY
$80.37
price up icon 0.15%
$59.62
price down icon 0.12%
$11.66
price down icon 0.77%
$75.38
price up icon 0.21%
$105.55
price up icon 1.46%
Cap:     |  Volume (24h):